within Pharmacolibrary.Drugs.ATC.V;

model V03AX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.63,
    Cl             = 1.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 150 / 1000000,
    adminCount     = 1,
    Vd             = 0.0024,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.021666666666666667,
    Tlag           = 21.0
  );

  annotation(Documentation(
    info ="<html><body><p>Cobicistat is a potent, selective inhibitor of cytochrome P450 3A (CYP3A) enzymes used as a pharmacokinetic enhancer (booster) for certain antiretroviral drugs, particularly HIV-1 protease inhibitors (such as atazanavir, darunavir) and the integrase inhibitor elvitegravir. Cobicistat has no activity against HIV-1 itself and is not used as monotherapy. It is currently approved and used in combination with other antiretrovirals.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers, mixed sex, single dose under fasting and fed (high fat meal) conditions.</p><h4>References</h4><ol><li><p>Vos, CF, et al., &amp; Ruhé, HG (2024). Increasing the bioavailability of oral esketamine by a single dose of cobicistat: A case study. <i>Pharmacotherapy</i> 44(6) 480–484. DOI:<a href=&quot;https://doi.org/10.1002/phar.2942&quot;>10.1002/phar.2942</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38819020/&quot;>https://pubmed.ncbi.nlm.nih.gov/38819020</a></p></li><li><p>Momper, JD, et al., &amp; Mirochnick, M (2018). Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. <i>AIDS (London, England)</i> 32(17) 2507–2516. DOI:<a href=&quot;https://doi.org/10.1097/QAD.0000000000001992&quot;>10.1097/QAD.0000000000001992</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30134297/&quot;>https://pubmed.ncbi.nlm.nih.gov/30134297</a></p></li><li><p>Elliot, ER, et al., &amp; Boffito, M (2019). Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat. <i>HIV research &amp; clinical practice</i> 20(3) 82–91. DOI:<a href=&quot;https://doi.org/10.1080/25787489.2019.1638077&quot;>10.1080/25787489.2019.1638077</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31335301/&quot;>https://pubmed.ncbi.nlm.nih.gov/31335301</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V03AX03;
